Revolution Medicines (RVMD) Current Leases (2020 - 2026)

Revolution Medicines' Current Leases history runs 7 years deep, the most recent figure standing at $16.6 million for Q1 2026.

• In Q1 2026, Current Leases rose 27.98% year-over-year to $16.6 million; the TTM figure through Mar 2026 stood at $16.6 million (up 27.98% YoY), while the FY2025 annual figure was $16.5 million, up 27.94% from the prior year.
• Current Leases was $16.6 million for Q1 2026 at Revolution Medicines, up from $16.5 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $16.6 million in Q1 2026 to a low of $5.7 million in Q2 2023.
• Historically, Current Leases has averaged $9.7 million across 5 years, with a median of $8.2 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Current Leases fell 17.98% in 2023, then soared 94.45% in 2025.
• A 5-year view of Current Leases shows it stood at $6.8 million in 2022, then grew by 8.8% to $7.4 million in 2023, then jumped by 74.68% to $12.9 million in 2024, then grew by 27.94% to $16.5 million in 2025, then climbed by 0.86% to $16.6 million in 2026.
• The last three Current Leases figures came in at $16.6 million (Q1 2026), $16.5 million (Q4 2025), and $16.3 million (Q3 2025), per Business Quant data.